The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of chimeric anti-GPC3 scFv-CD3ε engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma.
 
Yi Zheng
No Relationships to Disclose
 
Qihan Fu
No Relationships to Disclose
 
Qingwei Zhao
No Relationships to Disclose
 
Lulu Liu
No Relationships to Disclose
 
Zhou Tong
No Relationships to Disclose
 
Hangyu Zhang
No Relationships to Disclose
 
Peng Zhao
No Relationships to Disclose
 
Weijia Fang
No Relationships to Disclose
 
Xudong Zhu
No Relationships to Disclose
 
Wanwan Gao
Employment - CARsgen Therapeutics
 
Miya Wang
Employment - CARsgen Therapeutics
 
Daijing Yuan
Employment - CARsgen Therapeutics
 
Huamao Wang
Employment - CARsgen Therapeutics
Leadership - CARsgen Therapeutics
Stock and Other Ownership Interests - CARsgen Therapeutics
 
Zonghai Li
Employment - Zonghai Li
Leadership - Zonghai Li
Stock and Other Ownership Interests - Zonghai Li
 
Tingbo Liang
No Relationships to Disclose